Blog

IQoro shortlisted for Bionow Product of the Year Award

We are very proud to tell you that IQoro has been shortlisted in the category “Product of the Year” at the prestigious Bionow Awards that will be held in Manchester on March 7, 2024.  The event is a highlight of the life sciences calendar and celebrates the achievements of the sector, showcasing the very best […]

Read more

MYoroface named one of the fastest growing companies in Europe

MYoroface, the Swedish healthtech company behind the IQoro, has been named one of the fastest growing companies in Europe. The award comes from the annual FT 1000 report developed by The Financial Times, which ranks European companies that have achieved the highest growth in recent years. In the UK, around 13 million people suffer from […]

Read more

International Reflux Day highlights a serious health problem

More than 20% of the world’s population suffer from reflux and endure symptoms like heartburn, acid reflux and thick phlegm. In many cases, so severely that it is difficult to eat normally – or even to lie down and sleep. To draw attention to this growing, global problem, International Reflux Day has been instituted on […]

Read more

Swedish MedTech company MYoroface expands – innovative medical treatment for reflux now launched across the entire Nordic region

MYoroface is the Swedish MedTech company behind the unique innovation IQoro which treats the underlying cause of acid reflux, heartburn and more. IQoro has now been launched across all Nordic markets. Through a farsighted long-term global expansion strategy, the company wants to eventually address the fifth of the world’s population that suffer from acid reflux. […]

Read more

IQoro meets the new, more rigorous demands for the CE mark

A CE Mark is needed in order to introduce a MedTech product into the EU and currently the UK markets. Starting from 26th May 2021 the new MDR regulations 2017/745 will apply. These set higher demands on suppliers, but what will they mean for consumers? A summary of the new MDR regulations How has MYoroface […]

Read more

New neuromuscular treatment for hiatus hernia shortens intervention times for Healthcare Professionals and patients

Swedish Associate Professors Thomas Franzén and Mary Hägg have written a book chapter for IntechOpen, the world’s leading publisher of Open Access books. The conclusions are that reflux is most commonly caused by Hiatus hernia and that this can be treated successfully with neuromuscular training. The treatment also shortens intervention times for Healthcare Professionals as […]

Read more

Mary Hägg awarded Associate Professor status at Uppsala University

Scientist, innovator and registered dentist Mary Hägg has recently been awarded the title of Associate Professor in experimental ear, nose and throat diseases at Uppsala University. Her wide-ranging research centres on neuromuscular training and how it can be used to treat a range of conditions from hiatus hernia, reflux and sleep apnoea to speech and […]

Read more

UK Stroke Forum awards prize for scientific study on IQoro

The UK Stroke Forum, one of the largest European forums for researchers in stroke care, took place in December 2020. Among the 230 scientific studies submitted to the event, a jury selected a study on dysphagia by Associate Professor Mary Hägg of Uppsala University as winner of “Best Poster” prize. Every year more than 100,000 […]

Read more